+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost benefit analysis of routine mumps and rubella vaccination of israeli infants

Cost benefit analysis of routine mumps and rubella vaccination of israeli infants

Israel Journal of Medical Sciences 26(2): 74-80

Until January 1989, mumps vaccine was not routinely administered in Israel, and rubella immunization was restricted to adolescent girls. The theoretical effect of combined mumps-rubella vaccination was applied to a population consisting of a cohort of 1-year-old children followed for 13 years. Assuming 90% compliance and 95% vaccine efficacy, projected clinical cases of mumps, rubella, encephalitis and thrombocytopenia would be reduced by 4,144; 3,109; 13; and 1 respectively. We anticipate a benefit to cost ratio of between 1.17 and 1.77 for the program. Since only 10-20% of cases are reported, the true benefit to cost ratio is likely to be at least 5.85. The benefit to cost ratio based on health service benefits alone is between 0.34 and 0.52; however, after readjusting for under-reporting, benefits are expected to exceed costs. Expenditures for laboratory testing, a factor not previously considered in such an analysis, would be reduced by approximately .apprx.2,750 per year. These results justify the initiation in January 1989 of nationwide routine vaccination.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 007165525

Download citation: RISBibTeXText

PMID: 2108102

Related references

Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster. Clinical Therapeutics 37(4): 830-841.E7, 2016

Benefit-cost analysis of rubella vaccination policy. New England Journal of Medicine 294(6): 306-310, 1976

Mass vaccination against rubella in Iceland after cost-benefit analysis. Nordisk Medicin 94(8-9): 203-203, 1979

Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children. Clinical and Diagnostic Laboratory Immunology 11(5): 913-918, 2004

Cost-benefit analysis of alternative programs of vaccination against rubella in Israel. Public Health 98(3): 179-190, 1984

Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination. Plos One 9(2): E89361-E89361, 2015

Immunization of healthy children with mumps-rubella bivalent live vaccine and simultaneous vaccination with mumps-rubella and varicella vaccines. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 65(10): 1271-1275, 1991

A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 17(11-12): 1306-1311, 1999

Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: Decision from different perspectives. Vaccine 21(25-26): 3982-3987, 8 September, 2003

Estimated damage to the Israeli dairy herd caused by foot and mouth disease outbreaks and a cost/benefit analysis of the present vaccination policy. Israel Journal of Veterinary Medicine 49(1): 13-16, 1994

Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection. Msphere 3(5): -, 2018

Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months. Vaccine 13(18): 1759-1762, 1995

Effect of choice of measles-mumps-rubella vaccine on immediate vaccination pain in infants. Archives of Pediatrics & Adolescent Medicine 158(4): 323-326, 2004

A cost-benefit analysis of a routine varicella vaccination program for United States Air Force Academy cadets. Military Medicine 163(9): 631-634, 1998

Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II. Vaccine 24(31-32): 5800-5805, 2006